

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5526936

<b>SUBMISSION TYPE:</b>	CORRECTIVE ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Corrective Assignment to correct the ASSIGNEE'S NAME FROM DEL MAR PHARMACEUTICALS TO DEL MAR PHARMACEUTICALS (BC) LTD. previously recorded on Reel 041778 Frame 0259. Assignor(s) hereby confirms the ASSIGNMENT OF THEIR APPLICATION ENTITLED "ANALYTICAL METHOD FOR ANALYZING AND DETERMINING IMPURITIES IN DIANHYDROGALACTITOL".
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
BRI BIOPHARMACEUTICAL RESEARCH INC.	11/12/2016
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	DEL MAR PHARMACEUTICALS (BC) LTD.
<b>Street Address:</b>	720-999 WEST BROADWAY
<b>City:</b>	VANCOUVER, BRITISH COLUMBIA
<b>State/Country:</b>	CANADA
<b>Postal Code:</b>	V5Z 1K5
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	13933844
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(206)224-0779
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(206)695-1653
<b>Email:</b>	efiling@cojk.com
<b>Correspondent Name:</b>	GEORGE E. RENZONI, PH.D.
<b>Address Line 1:</b>	CHRISTENSEN O'CONNOR JOHNSON KINDNESS
<b>Address Line 2:</b>	1201 THIRD AVENUE, SUITE 3600
<b>Address Line 4:</b>	SEATTLE, WASHINGTON 98101
<b>ATTORNEY DOCKET NUMBER:</b>	DMPI-1-65922
<b>NAME OF SUBMITTER:</b>	MORRY DENTON
<b>SIGNATURE:</b>	/Morry Denton/
<b>DATE SIGNED:</b>	05/16/2019
<b>Total Attachments: 3</b>	
source=65922_Corrective_Assignment_5-16-19#page1.tif	

source=65922\_Corrective\_Assignment\_5-16-19#page2.tif

source=65922\_Corrective\_Assignment\_5-16-19#page3.tif

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4286089


<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	BRI BIOPHARMACEUTICAL RESEARCH INC.	11/12/2016
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	DEL MAR PHARMACEUTICALS	
<b>Street Address:</b>	720-999 WEST BROADWAY	
<b>City:</b>	VANCOUVER	
<b>State/Country:</b>	CANADA	
<b>Postal Code:</b>	V5Z 1K5	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	13933844
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(703)519-9958	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	7035199951	
<b>Email:</b>	docket@dcpatent.com	
<b>Correspondent Name:</b>	DITTHAVONG & STEINER, P.C.	
<b>Address Line 1:</b>	44 CANAL CENTER PLAZA SUITE 322	
<b>Address Line 4:</b>	ALEXANDRIA, VIRGINIA 22314	
<b>ATTORNEY DOCKET NUMBER:</b>	P6678US01	
<b>NAME OF SUBMITTER:</b>	MICHAEL B. FARBER	
<b>SIGNATURE:</b>	/Michael B. Farber/	
<b>DATE SIGNED:</b>	02/22/2017	
<b>Total Attachments: 2</b>		
source=P6678US01_Assignment2_filed#page1.tif		
source=P6678US01_Assignment2_filed#page2.tif		

**ASSIGNMENT**

**WHEREAS**, BRI Biopharmaceutical Research Inc., a Canadian corporation, whose place of business is located at 101—8898 Heather Street, Vancouver, British Columbia, Canada V6P 3S8, hereinafter referred to as "ASSIGNOR," is the owner of the entire right, title, and interest in: (1) a certain invention entitled "ANALYTICAL METHOD FOR ANALYZING AND DETERMINING IMPURITIES IN DIANHYDROGALACTITOL" for which a Patent Cooperation Treaty (PCT) application, PCT Patent Application Serial No. PCT/IB2013/000793, was filed on February 26, 2013 claiming priority from the US Provisional Application No. 61/603,464 filed on February 27, 2012; and (2) a certain invention entitled "IMPROVED ANALYTICAL METHODS FOR ANALYZING AND DETERMINING IMPURITIES IN DIANHYDROGALACTITOL" for which a Patent Cooperation Treaty (PCT) application, PCT Patent Application Serial No. PCT/US2014/066087, was filed on November 18, 2014 claiming priority from the US Provisional Application No. 61/603,464 filed on February 27, 2012; wherein both of the PCT patent applications referred to under (1) and (2) are hereinafter referred to as "PCT PATENT APPLICATIONS."

**Del Mar Pharmaceuticals (BC) Ltd.**


**WHEREAS**, ~~Del Mar Pharmaceuticals~~ <sup>Del Mar Pharmaceuticals (BC) Ltd.</sup>, a Canadian corporation, whose place of business is located at Suite 720-999 West Broadway, Vancouver, British Columbia, Canada V5Z 1K5, hereinafter referred to as "ASSIGNEE," is desirous of acquiring the entire right, title and interest in the PCT PATENT APPLICATIONS.

  
Attorney of Record  
1-10-19  
Date

**NOW, THEREFORE**, for valuable consideration, the receipt of which is hereby acknowledged, the ASSIGNOR, by these presents does hereby sell, assign, transfer, and set over unto the said ASSIGNEE, its successors and assigns, his full and exclusive right, title and interest in and to the said inventions and to the PCT PATENT APPLICATIONS. This Assignment also is effective with respect to all Letters Patent to be granted and issued therefore, including, but not limited to, all national and/or regional stage applications based on or claiming priority from the PCT PATENT APPLICATIONS, as well as all continuations, continuations in part, continuing prosecution and/or divisional applications, not only for, to and in the United States of America, its territories and possessions, but for, to, and in all other countries including

all priority rights under the International Convention for any corresponding application, including any application claiming priority from any previous application from which the PCT PATENT APPLICATIONS have claimed priority, as well as all priority rights under any other applicable laws or treaties and any national or regional stage applications based on applications filed under the International Convention or any other applicable laws or treaties for any corresponding application, including any application claiming priority from any previous application from which the PCT PATENT APPLICATIONS have claimed priority.

It is further agreed by the undersigned, upon the request of said ASSIGNEE, to execute any and all documents necessary to invest title in said applications and patents in said ASSIGNEE and to execute any and all documents necessary to maintain patent rights in any country or regional patent office in which a patent application or patent that claims priority from or claims the benefit of the PCT PATENT APPLICATIONS or any application claiming priority from any previous application from which the PCT PATENT APPLICATIONS have claimed priority has been filed or granted, including, but not limited to, documents in reissue proceedings, documents in reexamination proceedings, documents in opposition proceedings, or documents in any court actions in which the scope or validity of any such patent application or patent is at issue.

By: 

For: BRI Biopharmaceutical Research Inc.

Name: Dr. David Kwok

Date: 12 Nov 2016

Title: President & CEO, BRI Pharmaceutical Research Inc.


By: 

For: Del Mar Pharmaceuticals, Inc.

Name: Jeffrey A. Bacha

Date: 9-Dec/2016

Title: Chairman & CEO, ~~Del Mar Pharmaceuticals (BC) Ltd.~~  
~~Del Mar Pharmaceuticals (BC) Ltd.~~

  
Attorney of Record  
1-10-19  
Date

RECORDED: 02/22/2017

RECORDED: 05/16/2019

PATENT  
REEL: 041778 FRAME: 0261  
PATENT

REEL: 049212 FRAME: 0056